[
  {
    "date": "2023-12-30",
    "symbol": "MREO",
    "period": "FY",
    "netincomeloss": -29466000,
    "documenttype": "10-K",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "entityfilenumber": "001-38452",
    "entityregistrantname": "MEREO BIOPHARMA GROUP PLC",
    "entityincorporationstatecountrycode": "X0",
    "entityaddressaddressline1": "One Cavendish Place",
    "entityaddressaddressline2": "4th Floor",
    "entityaddresscityortown": "London",
    "entityaddresscountry": "GB",
    "entityaddresspostalzipcode": "W1G 0QF",
    "cityareacode": 44,
    "localphonenumber": "333-023-7300",
    "entitytaxidentificationnumber": "00-0000000",
    "security12btitle": "American Depositary Shares, each representing five ordinary shares, nominal value of  £0.003 per share",
    "security12gtitle": "None",
    "tradingsymbol": "MREO",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entityshellcompany": "false",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "true",
    "icfrauditorattestationflag": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityinteractivedatacurrent": "Yes",
    "auditorfirmid": 876,
    "auditorname": "PricewaterhouseCoopers LLP",
    "auditorlocation": "United Kingdom",
    "entitycentralindexkey": 1719714,
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "documentfiscalperiodfocus": "FY",
    "cashandcashequivalentsatcarryingvalue": 57421000,
    "prepaidexpenseandotherassetscurrent": 5156000,
    "researchanddevelopmentincentivesreceivablescurrent": 1183000,
    "assetscurrent": 63760000,
    "propertyplantandequipmentnet": 405000,
    "operatingleaserightofuseasset": 1245000,
    "finitelivedintangibleassetsnet": 1089000,
    "assets": 66499000,
    "accountspayablecurrent": 2346000,
    "accruedliabilitiescurrent": 5467000,
    "operatingleaseliabilitycurrent": 652000,
    "otherliabilitiescurrent": 1021000,
    "liabilitiescurrent": 9486000,
    "convertiblelongtermnotespayable": 4394000,
    "derivativeliabilitiesnoncurrent": 412000,
    "operatingleaseliabilitynoncurrent": 906000,
    "otherliabilitiesnoncurrent": 764000,
    "liabilities": 15962000,
    "commonstockvalue": 2775000,
    "treasurystockcommonvalue": 1230000,
    "additionalpaidincapital": 486107000,
    "retainedearningsaccumulateddeficit": -419630000,
    "accumulatedothercomprehensiveincomelossnetoftax": -17485000,
    "stockholdersequity": 50537000,
    "liabilitiesandstockholdersequity": 66499000,
    "commonstockparorstatedvaluepershare": 0.003,
    "commonstocksharesissued": 701217089,
    "commonstocksharesoutstanding": 701217089,
    "revenues": 10000000,
    "costofrevenues": 2574000,
    "researchanddevelopmentexpense": 17418000,
    "generalandadministrativeexpense": 18424000,
    "operatingincomeloss": -28416000,
    "investmentincomeinterest": 2131000,
    "interestexpense": 2881000,
    "gainlossonderivativeinstrumentsnetpretax": 245000,
    "foreigncurrencytransactiongainlossaftertax": -2347000,
    "othernonoperatingincomeexpense": -10000,
    "benefitfromresearchanddevelopmenttaxcredit": 1280000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -29998000,
    "incometaxexpensebenefit": -532000,
    "earningspersharebasic": -0.04,
    "earningspersharediluted": -0.04,
    "weightedaveragenumberofsharesoutstandingbasic": 659453921,
    "weightedaveragenumberofdilutedsharesoutstanding": 659453921,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 4202000,
    "comprehensiveincomenetoftax": -25264000,
    "sharebasedcompensation": 4924000,
    "depreciation": 171000,
    "amortizationofintangibleassets": 395000,
    "operatingleaserightofuseassetamortizationexpense": 495000,
    "fairvalueadjustmentofwarrants": -245000,
    "interestincome": 102000,
    "interestexpenses": 1942000,
    "foreigncurrencytransactiongainlossbeforetax": -2347000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -502000,
    "increasedecreaseinresearchanddevelopmenttaxesreceivable": -456000,
    "increasedecreaseinaccountspayable": -1263000,
    "increasedecreaseinaccruedliabilitiesandotheroperatingliabilities": -710000,
    "increasedecreaseinoperatingleaseliability": -578000,
    "netcashprovidedbyusedinoperatingactivities": -21132000,
    "paymentstoacquireintangibleassets": 419000,
    "netcashprovidedbyusedininvestingactivities": -419000,
    "proceedsfromotherequity": 100000,
    "proceedsfromissuanceofcommonstock": 11605000,
    "paymentsofstockissuancecosts": 511000,
    "paymentsofdebtissuancecosts": 33000,
    "repaymentsofconvertibledebt": 3188000,
    "netcashprovidedbyusedinfinancingactivities": 7973000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": -13579000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 57421000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents": 2818000,
    "interestpaidnet": 884000,
    "incometaxespaidnet": -1337000,
    "cashpaidfortheamountsincludedinthemeasurementofoperatingleaseliabilities": 759000,
    "conversionofstockamountconverted1": 5318000,
    "sharesoutstanding": 701217089,
    "othercomprehensiveincomelossnetoftax": 4202000,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 4924000,
    "stockissuedduringperiodsharesstockoptionsexercised": -79630,
    "stockissuedduringperiodvaluestockoptionsexercised": 105000,
    "stockissuedduringperiodsharesrestrictedstockawardgross": 501380,
    "stockissuedduringperiodvaluerestrictedstockawardgross": 3000,
    "stockissuedduringperiodsharesconversionofconvertiblesecurities": 27420095,
    "stockissuedduringperiodvalueconversionofconvertiblesecuritiesnetofadjustments": 108000,
    "stockissuedduringperiodsharesnewissues": 48367095,
    "stockissuedduringperiodvaluenewissues": 186000,
    "adjustmentstoadditionalpaidincapitalwarrantissued": 52000,
    "propertyplantandequipment": 100000,
    "eligibleresearchanddevelopmentexpenditurepercentage": 0.3335,
    "reducedresearchanddevelopmentexpenditurepercentage": 0.1753,
    "cashrebatereducedmaximumpercentage": 0.27,
    "totalexpenditurepercentage": 0.4,
    "totalexpenditurepercentageminimum": 0.186,
    "statutoryrestrictionpercentage": 0.65,
    "reducedcashrebatepercentage": 0.2167,
    "subcontractedexpenditurespercentage": 0.1209,
    "bespokeratespecifictothepatentboxregime": 0.1,
    "effectiveincometaxratecontinuingoperations": 0.0177,
    "propertyplantandequipmentusefullife": "P10Y",
    "propertyplantandequipmentbasisofvaluation": "straight-line method",
    "lesseeoperatingleaseremainingleaseterm": "P9Y",
    "businesscombinationcontingentconsiderationliability": 80000000,
    "financialliabilitiesfairvaluedisclosure": 412000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilityperiodincreasedecrease": 245000,
    "royaltyincomenonoperating": 302000000,
    "valueaddedtaxreceivablecurrent": 599000,
    "prepaidresearchanddevelopmentservices": 632000,
    "insurancesettlementsreceivable": 1950000,
    "securitydeposit": 615000,
    "otherprepaidexpensecurrent": 1360000,
    "propertyplantandequipmentgross": 710000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 800000,
    "intangibleassetscurrent": 1485000,
    "finitelivedintangibleassetsaccumulatedamortization": -396000,
    "intangibleassetsnetexcludinggoodwill": 1089000,
    "finitelivedintangibleassetsacquired1": 1500000,
    "increasedecreaseindeferredliabilities": 1500000,
    "operatingleasepayments": 800000,
    "operatingcostsandexpenses": 700000,
    "lesseeoperatingleaseliabilitypaymentsduenextrollingtwelvemonths": 778000,
    "lesseeoperatingleaseliabilitypaymentsdueinrollingyeartwo": 778000,
    "lesseeoperatingleaseliabilitypaymentsdueinrollingyearthree": 191000,
    "operatingleasesfutureminimumpaymentsdue": 1747000,
    "lesseeoperatingleaseliabilityundiscountedadjustmentamount": -189000,
    "operatingleaseliability": 1558000,
    "operatingleaseweightedaverageremainingleaseterm1": "P2Y6M",
    "operatingleaseweightedaveragediscountratepercent": 0.1,
    "accrualfortaxesotherthanincometaxescurrent": 280000,
    "deferredconsiderationliabilitycurrent": 711000,
    "otherliabilities": 30000,
    "accruedresearchanddevelopmentcosts": 1821000,
    "accruedlegalfees": 266000,
    "accruedbonusescurrentandnoncurrent": 1624000,
    "accruedauditfees": 671000,
    "accruedprofessionalfeescurrentandnoncurrent": 338000,
    "accruedincometaxes": 382000,
    "otheraccruedliabilitiescurrentandnoncurrent": 365000,
    "accruedliabilitiescurrentandnoncurrent": 5467000,
    "debtinstrumentconvertibleconversionprice1": 0.174,
    "debtinstrumentcarryingamount": 4600000,
    "convertibledebtfairvaluedisclosures": 3100000,
    "interestexpensedebt": 1000000,
    "debtinstrumentinterestrateeffectivepercentage": 0.278,
    "warrantliability": 412000,
    "fairvaluechangesduringtheyear": -245000,
    "warrantliabilityforeignexchange": -14000,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.02,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0336,
    "expectedlifeofshareoptionsgranted": "P5Y2M12D",
    "marketpriceofordinaryshares": 2.31,
    "descriptionofoptionpricingmodelshareoptionsgranted": "Black-Scholes",
    "exercisepriceperwarrants": 2.95,
    "fairvalueadjustmentsofwarrants": 500000,
    "classofwarrantnumberofsecuritiescalledbywarrants": 1243908,
    "numberofwarrantsoutstanding": 2487816,
    "percentageofissuedsharecapital": 0.004,
    "stockissuedduringperiodsharesperiodincreasedecrease": 48367095,
    "stockissuedduringperiodsharesconversionofunits": 27420095,
    "stockholdersequityperiodincreasedecrease": 186000,
    "stockissuedduringperiodvalueconversionofunits": 108000,
    "convertibledebtsecuritycarryingvalue": 7500000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 501380,
    "revenuefromcontractwithcustomerexcludingassessedtax": 9000000,
    "accruedmilestonepaymentcurrent": 100000,
    "costofrevenue": 2400000,
    "deferredtaxassetsandliabilitiespercent": 0.25,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "operatinglosscarryforwards": 30600000,
    "taxcreditcarryforwardamount": 14000000,
    "taxlossescarriedforward": 18200000,
    "uncertaintaxposition": 2900000,
    "researchdevelopmenttaxlossesforalternativeminimumtax": 0.2,
    "accumulatedtaxlossescarriedforward": 18200000,
    "preacquisitionlosscarryforwardlimit": 300000,
    "applicabletaxrate": 0.2352,
    "incomelossattributabletoparent": 8464000,
    "currentincometaxexpensebenefit": -2000,
    "effectiveincometaxratereconciliationpermanentdifferences": -0.054,
    "effectiveincometaxratereconciliationtaxcreditsresearch": -0.019,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.157,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": -0.007,
    "effectiveincometaxratereconciliationprioryearincometaxes": 0.019,
    "effectiveincometaxratereconciliationotheradjustments": 0.002,
    "deferredtaxassetsoperatinglosscarryforwards": 110604000,
    "deferredtaxassetspropertyplantandequipment": 17000,
    "deferredtaxassetsgoodwillandintangibleassets": 4248000,
    "deferredtaxassetsunrealizedlossesontradingsecurities": 56000,
    "deferredtaxassetdebtsecuritiesnontrading": 7000,
    "deferredtaxassetsloanrelationships": 553000,
    "deferredtaxassetsinprocessresearchanddevelopment": 79024000,
    "deferredtaxassetsstatetaxes": 4437000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 7487000,
    "deferredtaxassetsother": 23000,
    "deferredtaxassetsgross": 206344000,
    "deferredtaxassetsvaluationallowance": 206344000,
    "deferredtaxliabilitiesdepreciation": 32000,
    "deferredtaxliabilities": 32000,
    "deferredtaxassetsliabilitiesnet": 32000,
    "valuationallowancedeferredtaxassetchangeinamount": 9101000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 4700000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 2900000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardrequisiteserviceperiod1": "P1Y7M6D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P10Y",
    "shareoptioncontractualterm": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitedweightedaveragegrantdatefairvalue": 1.13,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodweightedaveragegrantdatefairvalue": 1.91,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodexercisableterm": "P180D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y1M6D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P7Y1M6D",
    "employeebenefitsandsharebasedcompensation": 4064000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 9595161,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 4874300,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 1324809,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 751672,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 3425209,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitednumberofshares": 6169952,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 1.63,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 1.03,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 1.57,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 1.42,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexpirationsinperiodweightedaverageexerciseprice": 2.82,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 2.27,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedweightedaverageexerciseprice": 1.27,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 1.41,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 0.92,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeituresweightedaveragegrantdatefairvalue": 1.27,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsexpiredweightedaveragegrantdatefairvalue": 2.35,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsexercisedweightedaveragegrantdatefairvalue": 1.29,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 8122000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisesinperiodtotalintrinsicvalue": 45000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsaggregateintrinsicvaluevested": 1463000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsoptionsaggregateintrinsicvaluenonvested": 6670000,
    "shareprice": 1.03,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0348,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.9824,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 489225,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 679225,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedinperiod": 100276,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedinperiod": 190000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageexerciseddatefairvalue": 1.02,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexercisableaggregateintrinsicvalue": 1130000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 54751240,
    "contractualobligation": 4200000
  },
  {
    "date": "2022-12-31",
    "symbol": "MREO",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MREO",
    "notradingsymbolflag": "true",
    "entityregistrantname": "MEREO BIOPHARMA GROUP PLC",
    "entitycentralindexkey": 1719714,
    "currentfiscalyearenddate": "December 31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Accelerated filer",
    "entityshellcompany": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entitycommonstocksharesoutstanding": 624928519,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "entityfilenumber": "001-38452",
    "entityincorporationstatecountrycode": "England and Wales",
    "contactpersonnelname": "Charles Sermon",
    "contactpersonnelemailaddress": "cs@mereobiopharma.com",
    "entityaddressaddressline1": "1 Cavendish Place",
    "entityaddressaddressline2": "4th Floor",
    "entityaddresscityortown": "London",
    "entityaddresscountry": "United Kingdom",
    "entityaddresspostalzipcode": "W1G 0QF",
    "cityareacode": 44,
    "localphonenumber": "333-023-7300",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "security12btitle": "Ordinary Shares, nominal value of £0.003 pershare",
    "securityexchangename": "The Nasdaq Stock Market LLC",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "documentregistrationstatement": "false",
    "icfrauditorattestationflag": "false",
    "auditorname": "BDO LLP",
    "auditorfirmid": 1295,
    "auditorlocation": "London",
    "costofsales": -936000,
    "researchanddevelopmentexpense": 24962000,
    "administrativeexpense": 19543000,
    "profitlossfromoperatingactivities": -43569000,
    "financeincome": 696000,
    "financecosts": 3361000,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorlossmandatorilymeasuredatfairvalue": 7805000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 1461000,
    "othergainslosses": 811000,
    "profitlossbeforetax": -79000,
    "incometaxexpensecontinuingoperations": -1897000,
    "profitlossattributabletoownersofparent": -34196000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 1828000,
    "comprehensiveincome": -1828000,
    "basicearningslosspershare": -0.06,
    "dilutedearningslosspershare": -0.06,
    "propertyplantandequipment": 28000,
    "intangibleassetsotherthangoodwill": -8889000,
    "noncurrentassets": 25947000,
    "currentprepayments": 3125000,
    "currenttaxassetscurrent": 1296000,
    "currentreceivablesfromtaxesotherthanincometax": 614000,
    "othercurrentreceivables": 762000,
    "cashandcashequivalents": 9000,
    "currentassets": 62131000,
    "assets": 88078000,
    "noncurrentwarrantliability": 129000,
    "noncurrentleaseliabilities": 1222000,
    "othernoncurrentliabilities": 182000,
    "noncurrentliabilities": 1533000,
    "tradeandothercurrentpayables": 3078000,
    "accruals": 4491000,
    "currentprovisions": 4822000,
    "shorttermborrowings": 11085000,
    "currentwarrantliability": 402000,
    "currentleaseliabilities": 466000,
    "othercurrentliabilities": 333000,
    "currentliabilities": 24677000,
    "liabilities": 26210000,
    "netassetsliabilities": 61868000,
    "issuedcapital": 100000,
    "sharepremium": 254303000,
    "capitalreserve": 132680000,
    "treasuryshares": 1058000,
    "otherreserves": 132680000,
    "retainedearnings": -331164000,
    "reserveofexchangedifferencesontranslation": -2169000,
    "equity": 100000,
    "adjustmentsfordepreciationandamortisationexpense": 727000,
    "adjustmentsforsharebasedpayments": 3862000,
    "adjustmentsforunrealisedforeignexchangelossesgains": -2064000,
    "adjustmentsforprovisions": 211000,
    "adjustmentsforfinancecosts": 2910000,
    "otheradjustmentsfornoncashitems": 647000,
    "adjustmentsforgainslossesonchangeinfairvalueremeasurementonwarrant": -7805000,
    "otheroperatingincomeexpense": 811000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 695000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 1126000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 1529000,
    "cashflowsfromusedinoperatingactivities": -38820000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 10000,
    "proceedsfromsalesofintangibleassetsclassifiedasinvestingactivities": 1484000,
    "interestreceivedclassifiedasinvestingactivities": 696000,
    "outflowsofcashfrominvestingactivities": 673000,
    "cashflowsfromusedininvestingactivities": 1497000,
    "proceedsfromissuingotherequityinstruments": 153000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 937000,
    "cashflowsfromusedinfinancingactivities": -784000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -38107000,
    "effectofexchangeratechangesoncashandcashequivalents": 145000,
    "othercomprehensiveincome": -1828000,
    "increasedecreasethroughsharebasedpaymenttransactions": 3862000,
    "issueofequity": 120000,
    "increasedecreasethroughexerciseofoptions": 82000,
    "increasedecreasethroughequitycomponentofconvertibleinstruments": 5958000,
    "increasedecreasethroughexerciseofwarrantsequity": 70000,
    "noncurrentassetsrecognisedasofacquisitiondate": 100000,
    "descriptionofusefullifepropertyplantandequipment": "shorter of lease term or ten years",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "two years",
    "contingentconsiderationfuturepotentialundiscountedpayments": 58600000,
    "nameofsubsidiary": "Mereo BioPharma Group plc Employee Benefit Trust",
    "descriptionofnatureofentitysoperationsandprincipalactivities": "Employee share scheme",
    "countryofincorporationorresidenceofsubsidiary": "Jersey",
    "proportionofownershipinterestinsubsidiary": 1,
    "milestonepaymentforregulatoryandcommercialachievements": 302000000,
    "milestonepaymenttoultragenyxcollaborationagreementdeductionscostsrecognised": 900000,
    "milestonepaymenttoultragenyxcollaborationagreementdeductionscostsyettoberecognised": 300000,
    "auditorsremunerationforauditservices": 371000,
    "auditorsremunerationforsubsidiaryaccounts": 49000,
    "auditrelatedassuranceservices": 59000,
    "depreciationrightofuseassets": 583000,
    "depreciationexcludingrightofuseassets": 144000,
    "wagesandsalaries": 4478000,
    "socialsecuritycosts": -606000,
    "postemploymentbenefitexpensedefinedbenefitplans": 124000,
    "expensefromsharebasedpaymenttransactionswithemployees": 3862000,
    "employeebenefitsexpense": 14194000,
    "keymanagementpersonnelsalariesandfeesexpense": 534000,
    "keymanagementpersonnelbenefitsinkind": 9000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 158000,
    "keymanagementpersonnelbonusexpense": 226000,
    "keymanagementpersonnelcompensation": 6900000,
    "bankinterestearned": 696000,
    "interestchargesonconvertibleloan": 2660000,
    "interestexpenseonleaseliabilities": 209000,
    "fairvalueincreaseordecreaseindeferredcashconsiderationprovision": 451000,
    "otherinterestcharges": 41000,
    "gainlossonchangeinfairvalueofwarrants": 7805000,
    "taxeffectofresearchanddevelopmentcredits": 1296000,
    "currenttaxexpenseincome": -601000,
    "descriptionofaccumulatedtaxlosses": "A deferred tax asset on losses has been recognized up to the level of the deferred tax liability, resulting in a net deferred tax liability of £nil.",
    "applicabletaxrate": 0.19,
    "taxrateeffectofdeferredtaxassetsandliability": 0.21,
    "taxlossescarriedforward": 4000000,
    "expirationdate": 2027,
    "offbalancesheetuncertaintaxpositiononunrecognizeddeferredtaxassetstaxcreditresearchanddevelopment": 3100000,
    "percentageofuncertaintaxpositiontotaxcreditresearchanddevelopmentclaims": 0.2,
    "accountingprofit": 6857000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 965000,
    "taxeffectofrevenuesexemptfromtaxation2011": 12000,
    "taxeffectofresearchanddevelopmentreliefuplift": -558000,
    "taxeffectoftaxlosses": 4810000,
    "taxeffectofforeigntaxrates": -422000,
    "taxeffectofdifferencesinoverseastaxrates": -323000,
    "taxeffectofcarrybacklossrelief": 649000,
    "taxeffectofadjustmentsforcurrenttaxofpriorperiods": -612000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 463000,
    "applicabletaxrates": 0.19,
    "deferredtaxliabilityasset": 176000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 156000,
    "profitlossattributabletoordinaryequityholdersofparententity": -34196000,
    "weightedaverageshares": 603196403,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -34196000,
    "adjustedweightedaverageshares": 603196403,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 10000,
    "disposalspropertyplantandequipment": -777000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 18000,
    "depreciationpropertyplantandequipment": 727000,
    "leaseliabilities": 1688000,
    "revisiontoestimatedvaluerecognisedinprofitorlossintangibleassetsotherthangoodwill": 448000,
    "increaseinprovisionfordeferredcashconsideration": 400000,
    "intangibleassetsunderdevelopment": 24116000,
    "industrystandardassetlife": "20 years",
    "descriptionofdiscountratesusedinpreviousestimateofvalueinuse": 0.15,
    "leasedeposits": 293000,
    "currentvalueaddedtaxreceivables": 362000,
    "miscellaneousreceivables": 107000,
    "cash": 5230000,
    "shorttermdepositsclassifiedascashequivalents": 51104000,
    "numberofdaysthresholdlimitofshorttermdeposits": 90,
    "tradeandothercurrentpayablestotradesuppliers": 2886000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 167000,
    "othercurrentpayables": 25000,
    "provisions": 402000,
    "arisingreleasedprovisions": 179000,
    "increasedecreasethroughtimevalueofmoneyadjustmentotherprovisions": 451000,
    "increasedecreasethroughforeignexchangeratesliabilitiesarisingfromfinancingactivities": 548000,
    "decreaseinprovisionduetochangeinestimates": -448000,
    "terminationbenefitsexpense": 200000,
    "numberofsharesissued": 40020280,
    "parvaluepershare": 0.003,
    "borrowingsinterestrate": 0.06,
    "issueofconvertibleinstruments": 1080000,
    "numberofconvertibleloannotesconvertedintoordinaryshares": 125061475,
    "convertibleloanamount": 18900000,
    "numberofwarrantsissued": 161048366,
    "percentagenumberofsharesissuable": 0.5,
    "exercisepriceperwarrants": 0.4144,
    "borrowingsmaturity": "June 30, 2023",
    "financialliabilitiesatfairvaluethroughprofitorloss": 4099999.9999999995,
    "notionalamount": 11900000,
    "warrantliability": 531000,
    "fairvaluechangesduringtheyear": -7805000,
    "expecteddividendaspercentageshareoptionsgranted": 0.24,
    "numberofwarrantsoutstanding": 147431351,
    "fairvalueadjustmentsofwarrants": 7600000,
    "fairvalueofthewarrantliability": 400000,
    "classofwarrantnumberofsecuritiescalledbywarrants": 1243908,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.96,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0196,
    "expectedlifeofshareoptionsgranted": 10,
    "marketpriceofordinaryshares": 0.75,
    "descriptionofoptionpricingmodelshareoptionsgranted": "Black-scholes",
    "convertibleloannotesissued": 4449000,
    "privateplacementloannotes": 6636000,
    "borrowings": 11085000,
    "issueofconvertibleinstrumentsshares": 21700000,
    "accretedinterestonbankloan": 13300000,
    "derivativefinancialliabilities": 63200000,
    "derecognitonoftheembeddedderivative": 41600000,
    "embeddedderivativeloannotesoutstanding": 33500000,
    "debthostinstrument": 6636000,
    "interestcostscapitalised": 1981000,
    "financialliabilitiesreclassifiedintoequity": 5958000,
    "numberofsharesissuedandfullypaid": 24783320,
    "increasedecreaseinnumberofsharesoutstanding": 40020280,
    "issuanceofsharecapitalforpublicoffering": 6843000,
    "sharesissuedpricepershare1": 0.174,
    "reserveofwarrantsissuedfortapfunding": 100000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 40900000,
    "mergerreserve": 40800000,
    "gainlossarisingfromdifferencebetweencarryingamountoffinancialliabilityextinguishedandconsiderationpaid": 33100000,
    "contractualcapitalcommitments": 900000,
    "numberofwarrantsissuedinexchangeforfunds": 1101683,
    "proceedsfromexerciseofwarrants": 200000,
    "sharebasedpaymentsreleaseforexerciseofoptions": -82000,
    "increasedecreaseinconversionoftheloannotes": -1005000,
    "liabilitiesarisingfromfinancingactivities": 18120000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -784000,
    "increasedecreasesettlementofliabilitiesfromfinancingactivities": -5958000,
    "changesthroughinterestexpenseinliabilitiesarisingfromfinancingacitivities": 3338000,
    "increasedecreasethroughequitycomponentsliabilitiesarisingfromfinancingactivities": -70000,
    "increasedecreasethroughchangesinfairvaluesliabilitiesarisingfromfinancingactivities": -8253000,
    "mreopercentageofincreasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 0.1,
    "percentageofreasonablypossibleincreaseinunobservableinputassets": 0.15,
    "percentageofweightedaverageprobability": 0.812,
    "increasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 600000,
    "undiscountedcontingentliabilityassociated": 80000000,
    "expectedvolatilitypercentage": 0.918,
    "financialliabilitiesatfairvalue": 300000,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 4491000,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": -79000,
    "fairvaluehierarchyvaluationdate": "December 31, 2022",
    "increasedecreasethroughnetexchangedifferencesotherprovisions": 508000,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibleincreaseinunobservableinputrecognisedinprofitorlossbeforetaxliabilities": -7593000,
    "cashandshorttermdeposits": 56334000,
    "otherreceivables": 400000,
    "financialassets": 56734000,
    "notesanddebenturesissued": 11086000,
    "tradeandotherpayables": 2911000,
    "financialliabilities": 20363000,
    "convertibledebtinstrumentconversionratio": 5,
    "shareoptioncontractualterm": 10,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 535488,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsperiod": 4.8,
    "percentageofoptionsissuedtoemployees": 0.75,
    "percentageofoptionsvestedtoemployees": 0.25,
    "shareoptionsvestingperiod": "three years",
    "percentageofannualbonus": 0.3,
    "numberofsharesissuedforconsideration": 1349693,
    "exercisepriceofoutstandingshareoptions2019": 3.59,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 22592,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 770805,
    "numberofoutstandingshareoptions": 100817,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 1.2,
    "sharebasedpaymentarrangementawardpaymentterm": 180,
    "numberoftradingdays": 30,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 0.99,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 0.1,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 78225,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 553160,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 3.49,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 1.01,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 3.32,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 3.49,
    "weightedaveragesharepriceshareoptionsgranted2019": 1.22,
    "cashheldbyemployeebenefittrust": 17741,
    "totalnumberofamericandepositorysharesusedtoexerciseoptionsbyebt": 200606,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 3699000,
    "keymanagementpersonnelcompensationsharebasedpayment": 3043000
  },
  {
    "date": "2021-12-31",
    "symbol": "MREO",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2021-12-31",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MREO",
    "notradingsymbolflag": "true",
    "entityregistrantname": "Mereo Biopharma Group plc",
    "entitycentralindexkey": 1719714,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entitycommonstocksharesoutstanding": 584908239,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "entityfilenumber": "001-38452",
    "entityincorporationstatecountrycode": "X0",
    "contactpersonnelname": "Charles Sermon",
    "contactpersonnelemailaddress": "cs@mereobiopharma.com",
    "entityaddressaddressline1": "One Cavendish Place",
    "entityaddressaddressline2": "4th Floor",
    "entityaddresscityortown": "London",
    "entityaddresscountry": "GB",
    "entityaddresspostalzipcode": "W1G 0QF",
    "cityareacode": 44,
    "localphonenumber": "333-023-7300",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "security12btitle": "American Depositary Shares, each representing five ordinary shares, nominal value of £0.003 per share",
    "securityexchangename": "NASDAQ",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "documentregistrationstatement": "false",
    "icfrauditorattestationflag": "false",
    "auditorname": "BDO LLP",
    "auditorfirmid": 1295,
    "auditorlocation": "Reading, United Kingdom",
    "revenue": 36464000,
    "costofsales": 17908000,
    "researchanddevelopmentexpense": 23559000,
    "administrativeexpense": 15933000,
    "profitlossfromoperatingactivities": -20936000,
    "financeincome": 1000,
    "financecosts": 4022000,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorlossmandatorilymeasuredatfairvalue": 40039000,
    "gainlossondisposalofintangibleassetsexplanatory": 113000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -954000,
    "profitlossbeforetax": 14241000,
    "incometaxexpensecontinuingoperations": 1516000,
    "profitlossattributabletoownersofparent": 12725000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 191000,
    "comprehensiveincome": 12534000,
    "basicearningslosspershare": 0.02,
    "dilutedearningslosspershare": -0.05,
    "propertyplantandequipment": 2530000,
    "intangibleassetsotherthangoodwill": 24564000,
    "noncurrentassets": 27094000,
    "currentprepayments": 2799000,
    "currentreceivablesfromtaxesotherthanincometax": 809000,
    "othercurrentreceivables": 1419000,
    "cashandcashequivalents": 94296000,
    "currentassets": 99323000,
    "assets": 126417000,
    "noncurrentprovisions": 1320000,
    "longtermborrowings": 14384000,
    "warrantliability": 8336000,
    "noncurrentleaseliabilities": 1754000,
    "othernoncurrentliabilities": 80000,
    "noncurrentliabilities": 25874000,
    "tradeandothercurrentpayables": 2499000,
    "accruals": 3826000,
    "currenttaxliabilitiescurrent": 1522000,
    "currentprovisions": 2803000,
    "currentleaseliabilities": 622000,
    "othercurrentliabilities": 1269000,
    "currentliabilities": 12541000,
    "liabilities": 38415000,
    "netassetsliabilities": 88002000,
    "issuedcapital": 1755000,
    "sharepremium": 247460000,
    "capitalreserve": 129835000,
    "treasuryshares": 1140000,
    "otherreserves": 7401000,
    "retainedearnings": -296968000,
    "reserveofexchangedifferencesontranslation": -341000,
    "equity": 88002000,
    "adjustmentsfordepreciationandamortisationexpense": 642000,
    "adjustmentsforsharebasedpayments": 3302000,
    "adjustmentsforunrealisedforeignexchangelossesgains": 954000,
    "adjustmentsforprovisions": 1385000,
    "adjustmentsforfinancecosts": 3797000,
    "otheradjustmentsfornoncashitems": 156000,
    "adjustmentsforgainslossesonchangeinfairvalueremeasurementonwarrant": -40039000,
    "gainlossondisposalofintangibleassets": 113000,
    "adjustmentsfordisposalofintangibleassets": 9457000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -589000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -1256000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -2825000,
    "cashflowsfromusedinoperatingactivities": -5239000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 535000,
    "proceedsfromsalesofintangibleassetsclassifiedasinvestingactivities": 113000,
    "interestreceivedclassifiedasinvestingactivities": 1000,
    "cashflowsfromusedininvestingactivities": -421000,
    "proceedsfromissuingshares": 78532000,
    "paymentsforshareissuecosts": 234000,
    "proceedsfromexerciseofoptions": 46000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 692000,
    "cashflowsfromusedinfinancingactivities": 77652000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 71992000,
    "effectofexchangeratechangesoncashandcashequivalents": -1165000,
    "othercomprehensiveincome": -191000,
    "issueofequity": 738000,
    "increasedecreaseinissuedsharecapitalandsharepremium": 601000,
    "increasedecreasethroughsharebasedpaymenttransactions": 3302000,
    "issuanceofsharecapitalforexerciseofshareoptions": -119000,
    "increasedecreasethroughequitycomponentofconvertibleinstruments": 137000,
    "noncurrentassetsrecognisedasofacquisitiondate": 100000,
    "descriptionofusefullifepropertyplantandequipment": "shorter of lease term or ten years",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P5Y",
    "contingentconsiderationfuturepotentialundiscountedpayments": 58600000,
    "nameofsubsidiary": "Mereo BioPharma 1 Limited",
    "descriptionofnatureofentitysoperationsandprincipalactivities": "Pharmaceutical R&D",
    "countryofincorporationorresidenceofsubsidiary": "UK",
    "proportionofownershipinterestinsubsidiary": 1,
    "upfrontpaymentreceived": 36500000,
    "milestonepaymentforregulatoryandcommercialachievements": 7200000,
    "milestonepaymenttoultragenyxcollaborationagreementdeductionscosts": 2400000,
    "milestonepaymenttoultragenyxcollaborationagreementdeductionscostsrecognised": 1100000,
    "milestonepaymenttoultragenyxcollaborationagreementdeductionscostsyettoberecognised": 1300000,
    "auditorsremunerationforauditservices": 358000,
    "auditorsremunerationforsubsidiaryaccounts": 46000,
    "auditrelatedassuranceservices": 57000,
    "depreciationrightofuseassets": 570000,
    "depreciationexcludingrightofuseassets": 72000,
    "averagenumberofemployees": 26,
    "wagesandsalaries": 4126000,
    "socialsecuritycosts": -402000,
    "postemploymentbenefitexpensedefinedbenefitplans": 73000,
    "expensefromsharebasedpaymenttransactionswithemployees": 1210000,
    "employeebenefitsexpense": 12183000,
    "keymanagementpersonnelsalariesandfeesexpense": 810000,
    "keymanagementpersonnelbenefitsinkind": 9000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 58000,
    "keymanagementpersonnelbonusexpense": 239000,
    "keymanagementpersonnelcompensation": 1116000,
    "bankinterestearned": 1000,
    "interestchargesonconvertibleloan": 3549000,
    "interestexpenseonleaseliabilities": 227000,
    "accretedinterestonbankloan": 13300000,
    "fairvalueincreaseordecreaseindeferredcashconsiderationprovision": 225000,
    "otherinterestcharges": 21000,
    "gainlossonchangeinfairvalueofwarrants": 39535000,
    "currenttaxexpenseincome": 1516000,
    "descriptionofaccumulatedtaxlosses": "A deferred tax asset on losses has been recognized up to the level of the deferred tax liability, resulting in a net deferred tax liability of £nil.",
    "applicabletaxrate": 0.19,
    "taxrateeffectofdeferredtaxassetsandliability": 0.25,
    "taxlossescarriedforward": 122600000,
    "expirationdate": 2022,
    "offbalancesheetuncertaintaxpositiononunrecognizeddeferredtaxassetstaxcreditresearchanddevelopment": 2600000,
    "percentageofuncertaintaxpositiontotaxcreditresearchanddevelopmentclaims": 0.2,
    "accountingprofit": -2706000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 708000,
    "taxeffectofrevenuesexemptfromtaxation2011": 78000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 65000,
    "taxeffectofresearchanddevelopmentreliefuplift": -1435000,
    "taxeffectoftaxlosses": 345000,
    "taxeffectofforeigntaxrates": -505000,
    "taxeffectofderecognitionofdeferredtax": -286000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -4000,
    "applicabletaxrates": 0.19,
    "deferredtaxliabilityasset": -44683000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 76000,
    "profitlossattributabletoordinaryequityholdersofparententity": 12725000,
    "weightedaverageshares": 527818648,
    "increasedecreasetoprofitlosstoreflectdilutiveeffectresultingfromassumedconversionofpotentialordinaryshares": -38523000,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -25798000,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 27457163,
    "adjustedweightedaverageshares": 555275811,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 923000,
    "increasedecreasethroughleasemodificationexplanatory": 133000,
    "disposalspropertyplantandequipment": 868000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -1000,
    "depreciationpropertyplantandequipment": 494000,
    "leaseliabilities": 622000,
    "revisiontoestimatedvaluerecognisedinprofitorlossintangibleassetsotherthangoodwill": -2373000,
    "increasedecreaseinlicenseofintangibleassets": -9457000,
    "increaseinprovisionfordeferredcashconsideration": 2400000,
    "intangibleassetsunderdevelopment": 2159000,
    "industrystandardassetlife": "20 years",
    "descriptionofdiscountratesusedinpreviousestimateofvalueinuse": 0.12,
    "rentdeposit": 408000,
    "currentvalueaddedtaxreceivables": 387000,
    "miscellaneousreceivables": 624000,
    "cash": 93727000,
    "shorttermdepositsclassifiedascashequivalents": 569000,
    "tradeandothercurrentpayablestotradesuppliers": 2285000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 190000,
    "othercurrentpayables": 24000,
    "provisions": 4123000,
    "arisingreleasedprovisions": -109000,
    "increasedecreasethroughtimevalueofmoneyadjustmentotherprovisions": 225000,
    "decreaseinprovisionduetochangeinestimates": -2373000,
    "numberofsharesissued": 40397976,
    "parvaluepershare": 0.174,
    "borrowingsinterestrate": 0.06,
    "issueofconvertibleinstruments": 40500000,
    "numberofconvertibleloannotesconvertedintoordinaryshares": 125061475,
    "convertibleloanamount": 18900000,
    "numberofwarrantsissued": 161048366,
    "percentagenumberofsharesissuable": 0.5,
    "exercisepriceperwarrants": 0.348,
    "borrowingsmaturity": "June 2023",
    "financialliabilitiesatfairvaluethroughprofitorloss": 4100000,
    "notionalamount": 38600000,
    "settledduringtheyear": -2400000,
    "fairvaluechangesduringtheyear": -40039000,
    "expecteddividendaspercentageshareoptionsgranted": 0.25,
    "numberofwarrantsoutstanding": 147431351,
    "fairvalueadjustmentsofwarrants": 39500000,
    "fairvalueofthewarrantliability": 8000000,
    "numberofwarrantsexercisedduringperiod": 15414626,
    "classofwarrantnumberofsecuritiescalledbywarrants": 1243908,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.75,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.009,
    "expectedlifeofshareoptionsgranted": "P1Y6M",
    "marketpriceofordinaryshares": 1.6,
    "descriptionofoptionpricingmodelshareoptionsgranted": "Black-Scholes",
    "convertibleloannotesissued": 3771000,
    "privateplacementloannotes": 10613000,
    "borrowings": 14384000,
    "issueofconvertibleinstrumentsshares": 21700000,
    "derivativefinancialliabilities": 63200000,
    "derecognitonoftheembeddedderivative": 41600000,
    "embeddedderivativeloannotesoutstanding": 33500000,
    "debthostinstrument": 10613000,
    "interestcostscapitalised": 2974000,
    "financialliabilitiesreclassifiedintoequity": 5307000,
    "numberofsharesissuedandfullypaid": 584908239,
    "increasedecreaseinnumberofsharesoutstanding": 245955098,
    "issuanceofsharecapitalforpublicoffering": 85909000,
    "transactioncostsforissuedsharecapital": 234000,
    "sharesissuedpricepershare1": 0.174,
    "reserveofwarrantsissuedfortapfunding": 100000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 40900000,
    "mergerreserve": 40800000,
    "gainlossarisingfromdifferencebetweencarryingamountoffinancialliabilityextinguishedandconsiderationpaid": 200000,
    "numberofwarrantsconverted": 4621147,
    "reductioninwarrantliability": 2400000,
    "transactioncostsassociatedwithissueofsharecapital": 200000,
    "numberofadsequivalentstowarrantsissuedduringperiod": 2990898,
    "sharebasedpaymentsreleaseforexerciseofoptions": -119000,
    "increasedecreaseinconversionoftheloannotes": -1722000,
    "liabilitiesarisingfromfinancingactivities": 2376000,
    "increasedecreasesettlementofliabilitiesfromfinancingactivities": -2400000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -692000,
    "changesthroughinterestexpenseinliabilitiesarisingfromfinancingacitivities": 230000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 910000,
    "increasedecreasethroughleasemodificationsarisingfromfinancingactivities": 163000,
    "increasedecreasethroughchangesinfairvaluesliabilitiesarisingfromfinancingactivities": -40039000,
    "increasedecreasethroughforeignexchangeratesliabilitiesarisingfromfinancingactivities": -29000,
    "mreopercentageofincreasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 0.1,
    "percentageofreasonablypossibleincreaseinunobservableinputassets": 0.12,
    "percentageofweightedaverageprobability": 0.406,
    "increasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 31000000,
    "undiscountedcontingentliabilityassociated": 80000000,
    "expectedvolatilitypercentage": 0.751,
    "financialliabilitiesatfairvalue": 4123000,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 781000,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": -84000,
    "fairvaluehierarchyvaluationdate": "2021-12-31",
    "increasedecreasesettlementofliabilitiesthroughotherprovisions": -2400000,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibleincreaseinunobservableinputrecognisedinprofitorlossbeforetaxliabilities": -39535000,
    "cashandshorttermdeposits": 94296000,
    "otherreceivables": 1032000,
    "financialassets": 95328000,
    "notesanddebenturesissued": 14384000,
    "tradeandotherpayables": 2309000,
    "financialliabilities": 12459000,
    "outstandingcommitmentsmadebyentityrelatedpartytransactions": 1400000,
    "convertibledebtinstrumentconversionratio": 5,
    "shareoptioncontractualterm": "P10Y",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 2696960,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsperiod": "P8Y8M12D",
    "percentageofoptionsissuedtoemployees": 0.75,
    "percentageofoptionsvestedtoemployees": 0.25,
    "shareoptionsvestingperiod": "P3Y",
    "percentageofannualbonus": 0.3,
    "numberofsharesissuedforconsideration": 1349693,
    "exercisepriceofoutstandingshareoptions2019": 1.76,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 253277,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 28521,
    "numberofoutstandingshareoptions": 3943702,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 727698,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 2.83,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 39333,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 2.88,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 2.66,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 5.37,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 2.11,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 3.16,
    "weightedaveragesharepriceshareoptionsgranted2019": 2.83,
    "cashheldbyemployeebenefittrust": 17866,
    "totalnumberofamericandepositorysharesusedtoexerciseoptionsbyebt": 31205,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 4018000,
    "keymanagementpersonnelcompensationsharebasedpayment": 2559000
  },
  {
    "date": "2020-12-31",
    "symbol": "MREO",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MREO",
    "entityregistrantname": "Mereo Biopharma Group plc",
    "entitycentralindexkey": 1719714,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entitycommonstocksharesoutstanding": 338953141,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "entityaddresscountry": "GB",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "security12btitle": "Common Shares",
    "securityexchangename": "NASDAQ",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "documentregistrationstatement": "false",
    "icfrauditorattestationflag": "false",
    "researchanddevelopmentexpense": 16347000,
    "administrativeexpense": 21222000,
    "profitlossfromoperatingactivities": -37569000,
    "financeincome": 44000,
    "financecosts": 6383000,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorlossmandatorilymeasuredatfairvalue": -109849000,
    "gainlossondisposalofintangibleassetsexplanatory": -10872000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -513000,
    "profitlossbeforetax": -372000,
    "incometaxexpensecontinuingoperations": -2822000,
    "profitlossattributabletoownersofparent": -163628000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": -349000,
    "othercomprehensiveincome": 349000,
    "comprehensiveincome": -163279000,
    "basicanddilutedearningslosspershare": -0.48,
    "propertyplantandequipment": -1811000,
    "intangibleassetsotherthangoodwill": -1357000,
    "noncurrentassets": 33221000,
    "currentprepayments": 1619000,
    "currenttaxassetscurrent": 2818000,
    "currentreceivablesfromtaxesotherthanincometax": 804000,
    "othercurrentreceivables": 1016000,
    "cashandcashequivalents": 5586000,
    "currentassets": 29726000,
    "assets": 62947000,
    "noncurrentprovisions": 1216000,
    "longtermborrowings": 16142000,
    "warrantliability": 800000,
    "othernoncurrentliabilities": 62000,
    "noncurrentleaseliabilities": 1158000,
    "noncurrentliabilities": 69353000,
    "tradeandothercurrentpayables": 3333000,
    "accruals": 4178000,
    "currentprovisions": 309000,
    "currentliabilities": 8565000,
    "currentleaseliabilities": 636000,
    "liabilities": 77918000,
    "netassetsliabilities": -14971000,
    "issuedcapital": 100000,
    "sharepremium": 161785000,
    "capitalreserve": 128374000,
    "treasuryshares": 1305000,
    "otherreserves": 128374000,
    "retainedearnings": -309693000,
    "reserveofexchangedifferencesontranslation": -150000,
    "equity": 1017000,
    "adjustmentsfordepreciationandamortisationexpense": 1599000,
    "adjustmentsforsharebasedpayments": 1558000,
    "adjustmentsforunrealisedforeignexchangelossesgains": 1821000,
    "adjustmentsforprovisions": 162000,
    "adjustmentsforfinancecosts": 6226000,
    "adjustmentsforfairvalueremeasurementgainonleasemodification": -957000,
    "adjustmentsforgainslossesonchangeinfairvalueremeasurementonwarrant": 109849000,
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": 10872000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 141000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -3551000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -10433000,
    "cashflowsfromusedinoperatingactivities": -28341000,
    "acquisitionofsubsidiary": -354000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 16000,
    "proceedsfromsalesofintangibleassetsclassifiedasinvestingactivities": 1821000,
    "interestreceivedclassifiedasinvestingactivities": 44000,
    "cashflowsfromusedininvestingactivities": 1495000,
    "proceedsfromissuingshares": 20136000,
    "paymentsforshareissuecosts": 1307000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 44375000,
    "paymentsfordebtissuecosts": 3598000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 19802000,
    "paymentsforloanandborrowingsissuecostexplanatory": 81000,
    "interestpaidclassifiedasfinancingactivities": 2900000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 2086000,
    "cashflowsfromusedinfinancingactivities": 34737000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 7891000,
    "effectofexchangeratechangesoncashandcashequivalents": 253000,
    "issueofequity": 16937000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -499000,
    "increasedecreasethroughsharebasedpaymenttransactions": 1558000,
    "increasedecreasethroughexerciseofwarrantsequity": 4080000,
    "increasedecreasethroughconversionofconvertibleinstruments": 1084000,
    "increasedecreasethroughequitycomponentofconvertibleinstruments": 1084000,
    "increasedecreaseinreclassificationofloannotesembeddedderivativeexplanatory": 33481000,
    "increasedecreasethroughconversionofexerciseofwarrantsequityexplanatory": 126000,
    "noncurrentassetsrecognisedasofacquisitiondate": 500000,
    "descriptionofusefullifepropertyplantandequipment": "shorter of lease term or ten years",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P2Y",
    "contingentconsiderationfuturepotentialundiscountedpayments": 80000000,
    "nameofsubsidiary": "Mereo BioPharma Group plc Employee Benefit Trust",
    "descriptionofnatureofentitysoperationsandprincipalactivities": "Pharmaceutical R&amp;D",
    "countryofincorporationorresidenceofsubsidiary": "Jersey",
    "proportionofownershipinterestinsubsidiary": 1,
    "auditorsremunerationforauditservices": 449000,
    "auditorsremunerationforsubsidiaryaccounts": 49000,
    "auditrelatedassuranceservices": 318000,
    "legalandprofessionalfees": 4619000,
    "gainonmodificationoflease": -957000,
    "incomefromsublease": -646000,
    "depreciationrightofuseassets": 1531000,
    "depreciationexcludingrightofuseassets": 68000,
    "numberofdirectors": 1,
    "averagenumberofemployees": 39,
    "wagesandsalaries": 3046000,
    "socialsecuritycosts": -397000,
    "postemploymentbenefitexpensedefinedbenefitplans": 66000,
    "expensefromsharebasedpaymenttransactionswithemployees": 1558000,
    "employeebenefitsexpense": 10669000,
    "keymanagementpersonnelsalariesandfeesexpense": 1114000,
    "keymanagementpersonnelbenefitsinkind": 14000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 144000,
    "keymanagementpersonnelbonusexpense": 538000,
    "keymanagementpersonnelcompensation": 5498000,
    "bankinterestearned": 5000,
    "gainsondisposalsofinvestments": 39000,
    "interestchargesonconvertibleloan": 2241000,
    "interestchargesonbankloan": 2900000,
    "interestexpenseonleaseliabilities": 1085000,
    "accretedinterestonbankloan": 13300000,
    "fairvalueincreaseordecreaseindeferredcashconsiderationprovision": 157000,
    "gainlossonchangeinfairvalueofwarrants": -109849000,
    "taxeffectofresearchanddevelopmentcredits": 2822000,
    "applicabletaxrate": 0.19,
    "taxrateeffectofdeferredtaxassetsandliability": 0.19,
    "taxlossescarriedforward": 136900000,
    "offbalancesheetuncertaintaxpositiononunrecognizeddeferredtaxassetstaxcreditresearchanddevelopment": 2500000,
    "percentageofuncertaintaxpositiontotaxcreditresearchanddevelopmentclaims": 0.2,
    "taxexpenseincomeatapplicabletaxrate": -31626000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 13270000,
    "taxeffectofrevenuesexemptfromtaxation2011": 4000,
    "taxeffectofresearchanddevelopmentreliefuplift": -1214000,
    "taxeffectoftaxlosses": 14479000,
    "taxeffectofforeigntaxrates": 184000,
    "taxeffectofdifferencesinoverseastaxrates": -261000,
    "taxeffectofderecognitionofdeferredtax": 2686000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 32000,
    "deferredtaxliabilityasset": 96000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -2590000,
    "weightedaverageshares": 338953141000,
    "ordinarysharesoutstanding": 1349692,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 162292274,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 16000,
    "increasedecreasethroughleasemodificationexplanatory": 1482000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 187000,
    "depreciationpropertyplantandequipment": 1599000,
    "leaseliabilities": 1794000,
    "decreasethroughclassifiedasheldforsaleintangibleassetsotherthangoodwill": 13386000,
    "revisiontoestimatedvaluerecognisedinprofitorlossintangibleassetsotherthangoodwill": 286000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 864000,
    "increaseinprovisionfordeferredcashconsideration": 300000,
    "upfrontpaymentreceived": 3100000,
    "gainlossondisposalofintangibleassets": -10900000,
    "derecognisedfinancialassets": 13400000,
    "additionalmilestonepaymentformanufacturingandcontrols": 302000000,
    "intangibleassetsunderdevelopment": 31648000,
    "industrystandardassetlife": "P20Y",
    "descriptionofdiscountratesusedinpreviousestimateofvalueinuse": 0.12,
    "rentdeposit": 407000,
    "currentvalueaddedtaxreceivables": 370000,
    "miscellaneousreceivables": 239000,
    "cash": 22922000,
    "shorttermdepositsclassifiedascashequivalents": 547000,
    "numberofsharesissuedandfullypaid": 338953141,
    "increasedecreaseinnumberofsharesoutstanding": 239179,
    "issuanceofsharecapitalforpublicoffering": -1307000,
    "sharesissuedpricepershare1": 0.08,
    "issueofconvertibleinstruments": 21800000,
    "reserveofwarrantsissuedfortapfunding": 100000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 40900000,
    "mergerreserve": 40800000,
    "numberofconvertibleloannotesconvertedintoordinaryshares": 2862595,
    "gainlossarisingfromdifferencebetweencarryingamountoffinancialliabilityextinguishedandconsiderationpaid": 33100000,
    "stockissuedduringperiodsharesnewissues": 47835,
    "increasedecreaseinconversionoftheloannotes": 33104000,
    "increasedecreaseinreclassificationsofremainingembeddedderivative": 33481000,
    "borrowingsinterestrate": 0.06,
    "convertibleloanamount": 18900000,
    "numberofwarrantsissued": 161048366,
    "percentagenumberofsharesissuable": 0.5,
    "exercisepriceperwarrants": 0.4144,
    "borrowingsmaturity": "June 2023",
    "financialliabilitiesatfairvaluethroughprofitorloss": 4100000,
    "notionalamount": 11900000,
    "convertibleloannotesissued": 3196000,
    "privateplacementloannotes": 12946000,
    "borrowings": 16142000,
    "issueofconvertibleinstrumentsshares": 21700000,
    "numberofmonthlyinstallments": 23,
    "loaninterestrate": 0.085,
    "reserveofequitycomponentofconvertibleinstruments": 1100000,
    "derivativefinancialliabilities": 63200000,
    "derecognitonoftheembeddedderivative": 41600000,
    "embeddedderivativeloannotesoutstanding": 33500000,
    "liabilitycomponentatdateofissue": 24417000,
    "interestcostscapitalised": 1803000,
    "financialliabilitiesreclassifiedintoequity": 13274000,
    "debthostinstrument": 12946000,
    "creditderivativearisingduringperiod": 11913000,
    "creditderivativefairvaluemovementsrecordedinprofitorloss": 63158000,
    "creditderivativereclassifiedtoequity": -75071000,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.85,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0005,
    "probabilityofresolutionspassing": 82.12,
    "descriptionofmethodusedandassumptionsmadetoincorporateeffectsofexpectedearlyexerciseshareoptionsgranted": "&#8212;  ",
    "provisions": 1525000,
    "arisingreleasedprovisions": 5000,
    "increasedecreasethroughtimevalueofmoneyadjustmentotherprovisions": 157000,
    "decreaseinprovisionduetochangeinestimates": 286000,
    "warrantliabilityissuedduringtheyear": 4080000,
    "settledduringtheyear": -127000,
    "fairvaluechangesduringtheyear": 46691000,
    "expecteddividendaspercentageshareoptionsgranted": 0.48,
    "numberofwarrantsoutstanding": 162845977,
    "fairvalueadjustmentsofwarrants": 46000000,
    "fairvalueofthewarrantliability": 49900000,
    "expectedlifeofshareoptionsgranted": "P3Y",
    "marketpriceofordinaryshares": 3.58,
    "descriptionofoptionpricingmodelshareoptionsgranted": "Black Scholes",
    "tradeandothercurrentpayablestotradesuppliers": 3165000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 146000,
    "othercurrentpayables": 22000,
    "liabilitiesarisingfromfinancingactivities": 12946000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 36330000,
    "increasedecreasethroughforeignexchangeratesliabilitiesarisingfromfinancingactivities": 438000,
    "increasedecreasethroughchangesinfairvaluesliabilitiesarisingfromfinancingactivities": 63158000,
    "changesthroughinterestexpenseinliabilitiesarisingfromfinancingacitivities": 1803000,
    "increasedecreasethroughnoncashbankmodificationlossliabilitiesarisingfromfinancingactivities": -9547000,
    "increasedecreasesettlementofliabilitiesfromfinancingactivities": -127000,
    "increasedecreasethroughreclassifiedtoequity": -88345000,
    "mreopercentageofincreasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 0.1,
    "milestonepaymentforregulatoryandcommercialachievements": 400000,
    "fairvaluehierarchyvaluationdate": "2020-12-31",
    "financialliabilitiesatfairvalue": 52900000,
    "increasedecreasesettlementofliabilitiesthroughotherprovisions": -354000,
    "percentageofreasonablypossibleincreaseinunobservableinputassets": 0.12,
    "percentageofweightedaverageprobability": 0.138,
    "percentageofincreasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 0.1,
    "increasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 400000,
    "undiscountedcontingentliabilityassociated": 80000000,
    "expectedvolatilitypercentage": 0.938,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 5590000,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": -372000,
    "convertibledebtinstrumentconversionratio": 5,
    "shareoptioncontractualterm": "P10Y",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 77000,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsperiod": "P4Y7M6D",
    "percentageofoptionsissuedtoemployees": 0.75,
    "percentageofoptionsvestedtoemployees": 0.25,
    "shareoptionsvestingperiod": "P3Y",
    "employeeservicesexpenses": 100000,
    "percentageofannualbonus": 0.3,
    "numberofsharesissuedforconsideration": 1349693,
    "numberofsharesgrantedbutnotyetissued": 429448,
    "exercisepriceofoutstandingshareoptions2019": 1.26,
    "fairvalueofordinarysharesbutnotyetissued": 3.1,
    "numberofsharesgrantedamount": 1.3,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 4584,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 3.03,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 1.32,
    "numberofoutstandingshareoptions": 163000,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 62170,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.33,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 427324,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 3.14,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 5.4,
    "weightedaveragesharepriceshareoptionsgranted2019": 1.84,
    "leasetermperiod": "P2Y",
    "americandepositaryshareheldbyemployeebenefittrust": 247456,
    "cashheldbyemployeebenefittrust": 21762000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 4479000,
    "keymanagementpersonnelcompensationsharebasedpayment": 875000,
    "proceedsfromissuingotherequityinstruments": 108200000,
    "milestonepaymenttoultragenyxcollaborationagreement": 7300000
  },
  {
    "date": "2019-12-31",
    "symbol": "MREO",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MREO",
    "entityregistrantname": "Mereo Biopharma Group plc",
    "entitycentralindexkey": 1719714,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entitycommonstocksharesoutstanding": 97959622,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "entityaddresscountry": "GB",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "security12btitle": "Common Shares",
    "securityexchangename": "NASDAQ",
    "researchanddevelopmentexpense": 23608000,
    "administrativeexpense": 15909000,
    "profitlossfromoperatingactivities": -39517000,
    "netincomerecognisedonacquisitionofsubsidiaryconsistingofgainonbargainpurchaseandtransactioncosts": 1035000,
    "financeincome": 377000,
    "financecosts": 3496000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -1037000,
    "profitlossbeforetax": 20000,
    "incometaxexpensecontinuingoperations": -6274000,
    "profitlossattributabletoownersofparent": -34844000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 499000,
    "othercomprehensiveincome": -499000,
    "comprehensiveincome": -35343000,
    "basicanddilutedearningslosspershare": -0.39,
    "propertyplantandequipment": 515000,
    "intangibleassetsotherthangoodwill": 45527000,
    "noncurrentassets": 56014000,
    "currentprepayments": 2111000,
    "currenttaxassetscurrent": 10426000,
    "currentreceivablesfromtaxesotherthanincometax": 979000,
    "othercurrentreceivables": 572000,
    "cashandcashequivalents": 4000,
    "currentassets": 30435000,
    "assets": 86449000,
    "issuedcapital": 100000,
    "sharepremium": 121684000,
    "capitalreserve": 59147000,
    "treasuryshares": 1305000,
    "otherreserves": 7000000,
    "retainedearnings": -146065000,
    "reserveofexchangedifferencesontranslation": -499000,
    "equity": 294000,
    "noncurrentprovisions": 104000,
    "longtermborrowings": 5373000,
    "warrantliability": 131000,
    "othernoncurrentliabilities": 44000,
    "noncurrentleaseliabilities": 9318000,
    "noncurrentliabilities": 16315000,
    "tradeandothercurrentpayables": 6352000,
    "accruals": 5138000,
    "currentprovisions": 309000,
    "shorttermborrowings": 15139000,
    "contingentconsiderationliability": 354000,
    "currentleaseliabilities": 2586000,
    "currentliabilities": 29878000,
    "liabilities": 46193000,
    "equityandliabilities": 86449000,
    "adjustmentsfordepreciationandamortisationexpense": 1577000,
    "adjustmentsforsharebasedpayments": 1636000,
    "adjustmentsforunrealisedforeignexchangelossesgains": -483000,
    "adjustmentsforprovisionforsocialsecuritycontributionsonemployeeshareoptions": -738000,
    "adjustmentsforprovisionfordeferredcashconsideration": 221000,
    "adjustmentsforinterestincome": 377000,
    "adjustmentsforfinancecosts": 3731000,
    "adjustmentsformodificationgainonbankloan": 456000,
    "adjustmentsforfairvalueremeasurementoncontingentconsideration": -3681000,
    "fairvalueremeasurementoncontingentconsideration": -354000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -936000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -6730000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -1069000,
    "cashflowsfromusedinoperatingactivities": -45931000,
    "cashandcashequivalentsinsubsidiaryorbusinessesacquiredordisposed2013": 10074000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 21000,
    "cashflowsfromusedindecreaseincreaseinshorttermdepositsandinvestments": 32865000,
    "interestreceivedclassifiedasinvestingactivities": 377000,
    "cashflowsfromusedininvestingactivities": 43295000,
    "paymentsforshareissuecosts": 761000,
    "interestpaidclassifiedasfinancingactivities": 1739000,
    "paymentstoacquireorredeementitysshares": 998000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 2212000,
    "cashflowsfromusedinfinancingactivities": -5710000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -8346000,
    "effectofexchangeratechangesoncashandcashequivalents": -349000,
    "issueofequity": 80000,
    "increasedecreaseinissuedsharecapitalandsharepremium": -1590000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -499000,
    "increasedecreasethroughsharebasedpaymenttransactions": 1636000,
    "increasedecreasethroughconversionofconvertibleinstruments": -310000,
    "shareissuerelatedcost": 761000,
    "increasedecreasethroughequitycomponentofconvertibleinstruments": -310000,
    "purchaseoftreasuryshares": 998000,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P2Y",
    "reclassificationofmodificationgainlossonbankloanfromadministrativeexpensesintofinancecharges": 700000,
    "noncurrentassetsrecognisedasofacquisitiondate": 22400000,
    "contingentconsiderationfairvalue": 400000,
    "contingentconsiderationfuturepotentialundiscountedpayments": 80000000,
    "shorttermleaseterm": "P12M",
    "rightofuseassets": 2600000,
    "cashoutflowforleases": 2200000,
    "rightofuseassetsincreasedecreaseinrevaluationsurplus": 300000,
    "depreciationrightofuseassets": 1505000,
    "interestexpenseonleaseliabilities": 1314000,
    "lossgainforeignexchangeonoperatinglease": 29000,
    "incomefromsubleasingrightofuseassets": 855000,
    "descriptionofconditionsforadditionalconsiderationpayable": "Additional cash consideration becomes payable under a contingent value rights (&#8220;CVR&#8221;) agreement, if, within eighteen months following the completion date, the Group enters into eligible partnership or investment transactions in relation to OncoMed&#8217;s navicixizumab product and, within five years of the completion date, the Group receives certain eligible cash milestone payment (&#8220;Navi Milestone&#8221;).",
    "acquisitionrelatedcostsrecognisedasexpensefortransactionrecognisedseparatelyfromacquisitionofassetsandassumptionofliabilitiesinbusinesscombination": 2600000,
    "revenueofcombinedentity": 3300000,
    "transactioncostsdirectlyattributableforissuanceofnewsharecapital": 800000,
    "profitlossofcombinedentity": 42900000,
    "shareofprofitlossofassociatesandjointventuresaccountedforusingequitymethod": 1000000,
    "navimilestonefairvalue": 400000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 40900000,
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofsubsidiary": "Navi Subsidiary, Inc.",
    "descriptionofnatureofentitysoperationsandprincipalactivities": "Pharmaceutical R&amp;D",
    "countryofincorporationorresidenceofsubsidiary": "U.S.",
    "auditorsremunerationforauditservices": 514000,
    "auditorsremunerationforsubsidiaryaccounts": 45000,
    "auditrelatedassuranceservices": 311000,
    "legalandprofessionalfees": 2413000,
    "depreciationexcludingrightofuseassets": 52000,
    "numberofdirectors": 2,
    "averagenumberofemployees": 46,
    "wagesandsalaries": 3384000,
    "socialsecuritycontributions": 124000,
    "postemploymentbenefitexpensedefinedbenefitplans": 114000,
    "expensefromsharebasedpaymenttransactionswithemployees": 1636000,
    "employeebenefitsexpense": 8007000,
    "keymanagementpersonnelsalariesandfeesexpense": 1106000,
    "keymanagementpersonnelbenefitsinkind": 17000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 25000,
    "keymanagementpersonnelbonusexpense": 294000,
    "keymanagementpersonnelcompensation": 1442000,
    "bankinterestearned": 42000,
    "interestearnedonshortterminvestments": 141000,
    "gainsondisposalsofinvestments": 194000,
    "interestchargesonconvertibleloan": 20000,
    "interestchargesontapfunding": 10000,
    "interestchargesonbankloan": 1739000,
    "accretedinterestonbankloan": 1523000,
    "modificationgainlossonbankloan": -456000,
    "fairvalueincreaseordecreaseindeferredcashconsiderationprovision": 221000,
    "gainlossonchangeinfairvalueofwarrants": 875000,
    "taxeffectofresearchanddevelopmentcredits": 5149000,
    "othertaxincomeexpense": 1125000,
    "explanationofchangesinapplicabletaxratestopreviousaccountingperiod": "A reduction in the rate of UK corporation tax to 19% from April 1, 2017 and to 17% from April 1, 2020 has been substantively enacted.",
    "applicabletaxrate": 0.19,
    "taxlossescarriedforward": 3200000,
    "receivablesfromtaxesotherthanincometax": 1100000,
    "expirationdate": 2028,
    "offbalancesheetuncertaintaxpositiononunrecognizeddeferredtaxassetstaxcreditresearchanddevelopment": 2500000,
    "percentageofuncertaintaxpositiontotaxcreditresearchanddevelopmentclaims": 0.2,
    "taxexpenseincomeatapplicabletaxrate": -7812000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 317000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 343000,
    "taxeffectofresearchanddevelopmentreliefuplift": -2540000,
    "taxeffectoftaxlosses": 4380000,
    "taxeffectofdeferredincomefrommbgloanguaranteecosts": 54000,
    "taxeffectofdifferencesinoverseastaxrates": 340000,
    "taxeffectfromgainonbargainpurchase": 699000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -23000,
    "deferredtaxliabilityasset": 2686,
    "increasedecreasethroughlossofcontrolofsubsidiarydeferredtaxliabilityasset": -2686,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 2686,
    "weightedaverageshares": 89424476,
    "ordinarysharesoutstanding": 1349692,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 321444,
    "additionstorightofuseassets": 10800000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 21000,
    "increaseduetotransferofassetsifrs16": 2551000,
    "acquisitionsthroughbusinesscombinationspropertyplantandequipment": 10837000,
    "disposalspropertyplantandequipment": 18000,
    "adjustmenttocarryingvalue": -290000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -115000,
    "depreciationpropertyplantandequipment": 1577000,
    "acquisitionsthroughbusinesscombinationsintangibleassetsotherthangoodwill": 12693000,
    "revisiontoestimatedvaluerecognisedinprofitorlossintangibleassetsotherthangoodwill": 698000,
    "impairmentlossrecognisedinprofitorlossintangibleassetsandgoodwill": -1071000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": -171000,
    "increaseinprovisionfordeferredcashconsideration": 700000,
    "intangibleassetsunderdevelopment": 12522000,
    "industrystandardassetlife": "P20Y",
    "descriptionofdiscountratesusedinpreviousestimateofvalueinuse": 0.153,
    "rentdeposit": 293000,
    "currentvalueaddedtaxreceivables": 269000,
    "miscellaneousreceivables": 10000,
    "cash": 15803000,
    "shorttermdepositsclassifiedascashequivalents": 544000,
    "numberofsharesissuedandfullypaid": 24783320,
    "parvaluepershare": 0.003,
    "reserveofwarrantsissuedfortapfunding": 44156000,
    "mergerreserve": 40800000,
    "issuanceofsharecapitalforconversionofloannote": 3953000,
    "transactioncostsforissuedsharecapital": 761000,
    "increasedecreasethroughacquisitionformergerreserve": 40818000,
    "accumulateddeficitsandotherreserve": -139065000,
    "loansreceived": 20512000,
    "borrowings": 20512000,
    "numberofmonthlyinstallments": 23,
    "loanmaturitydate": "March&#160;1, 2021",
    "loaninterestrate": 0.085,
    "borrowingsprincipalamount": 20500000,
    "provisions": 354000,
    "provisionreleasedotherprovisions": 738000,
    "increasedecreasethroughtimevalueofmoneyadjustmentotherprovisions": 221000,
    "decreaseinprovisionduetochangeinestimates": -698000,
    "warrantliabilityissuedduringtheyear": 131000,
    "warrantliabilitymovementduringtheyear": -1006000,
    "expecteddividendaspercentageshareoptionsgranted": 0.0127,
    "numberofwarrantsoutstanding": 1243908,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.66,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0095,
    "expectedlifeofshareoptionsgranted": "P10Y",
    "marketpriceofordinaryshares": 0.83,
    "descriptionofoptionpricingmodelshareoptionsgranted": "Black Scholes",
    "otherliabilities": 44000,
    "interestaccretion": 10000,
    "tradeandothercurrentpayablestotradesuppliers": 6148000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 183000,
    "othercurrentpayables": 21000,
    "liabilitiesarisingfromfinancingactivities": 34599000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -3951000,
    "increasedecreasethroughforeignexchangeratesliabilitiesarisingfromfinancingactivities": -131000,
    "increasedecreasethroughchangesinfairvaluesliabilitiesarisingfromfinancingactivities": -987000,
    "changesthroughinterestexpenseinliabilitiesarisingfromfinancingacitivities": 4596000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 2534000,
    "increasedecreasethroughgainonmodificationarisingfromfinancingactivities": -457000,
    "increasedecreasethroughissuanceofequityarisingfromfinancingactivities": -2058000,
    "increasedecreasethroughobtainingorlosingcontrolofsubsidiariesorotherbusinessesliabilitiesarisingfromfinancingactivities": 10689000,
    "increasedecreasethroughleasetermreassessmentfromfinancingactivities": -290000,
    "maximumexposuretocreditriskwithonecounterparty": 10000000,
    "maximumexposuretocreditriskwithdepositcounterparty": 5000000,
    "mreopercentageofincreasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 0.1,
    "fairvaluehierarchyvaluationdate": "2019-12-31",
    "financialliabilitiesatfairvalue": 131000,
    "financialliabilities": 20512000,
    "changeinprovisionduetochangeinestimatesrecognizedinadministrativeexpense": 354000,
    "percentageofreasonablypossibleincreaseinunobservableinputassets": 0.153,
    "percentageofweightedaverageprobability": 0.95,
    "percentageofincreasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 0.1,
    "increasedecreaseinsensitivityanalysisaffectinginputtofairvalue": 400000,
    "undiscountedcontingentliabilityassociated": 80000000,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 49670000,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": 20000,
    "convertibledebtinstrumentconversionratio": 5,
    "shareoptioncontractualterm": "P10Y",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 77000,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsperiod": "P1Y7M6D",
    "weightedaveragefairvalueatmeasurementdateshareoptionsgranted": 0.49,
    "percentageofoptionsissuedtoemployees": 0.75,
    "percentageofoptionsvestedtoemployees": 0.25,
    "shareoptionsvestingperiod": "P3Y",
    "employeeservicesexpenses": 100000,
    "percentageofannualbonus": 0.3,
    "numberofsharesissuedforconsideration": 1349693,
    "numberofsharesgrantedbutnotyetissued": 429448,
    "exercisepriceofoutstandingshareoptions2019": 3.25,
    "fairvalueofordinarysharesbutnotyetissued": 3.1,
    "numberofsharesgrantedamount": 1.3,
    "adjustmentsforcumulativecompensationexpense": 100000,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 241374,
    "numberofoutstandingshareoptions": 163000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 357490,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 40141,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 3.07,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 4.2,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 5.4,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 3.21,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 3.03,
    "weightedaveragesharepriceshareoptionsgranted2019": 0.66,
    "undiscountedoperatingleasepaymentstobereceived": 552000,
    "lesseeoperatingleaseremainingleaseterm": "P12M",
    "leasetermperiod": "P2Y",
    "amountspayablerelatedpartytransactions": 1000000,
    "numberofsharespurchasedbyentity": 1074274,
    "cashheldbyemployeebenefittrust": 21762000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 3488000,
    "keymanagementpersonnelcompensationsharebasedpayment": 1152000,
    "contingentconsiderationpayable": 500000
  }
]